{
  "id": 16771958,
  "title": "Targeted drug significantly delays advanced breast cancer progression but increases toxicity, phase III trial reports",
  "url": "https://urgent.news/2026/10/27/targeted-drug-significantly-delays-advanced-breast-cancer-progression",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-27T16:40:01.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-10-drug-significantly-delays-advanced-breast.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "In a global phase 1 trial, trastuzumab rezetecan showed promising signs of fighting ERBB2-low metastatic breast cancer in patients who had already undergone extensive treatment. Also known as HER2-low breast cancer, this subtype is characterized by low levels of HER2, a growth factor protein that can still be targeted for treatment. Trastuzumab rezetecan is an antibody-drug conjugate (ADC) that…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}